|
| Investigators showed a DNA methylation signature for HCC detection in liquid biopsies, distinct from normal tissues and blood profiles.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Single-nucleus RNA sequencing analysis revealed pathways involved in fatty acid oxidation in DNA methyltransferases (Dnmt1)-deficient hepatocytes.
[Advanced Science] |
|
|
|
| Herein investigators found that ferroptosis inducers sorafenib and erastin could enhance cuproptosis in primary liver cancer cells by increasing copper dependent lipoylated protein aggregation.
[Journal Of Experimental & Clinical Cancer Research] |
|
|
|
| The efficient downregulation of autophagy-related gene 7 led to an excellent antifibrotic effect both in vitro and in vivo.
[ACS Applied Materials & Interfaces] |
|
|
|
| Scientists used label-free Raman microscopy to assess human induced pluripotent stem cell differentiation into hepatocyte lineage based on the intracellular chemical content.
[Analytical Chemistry] |
|
|
|
| The authors observed the histopathological features of the progression of NASH to liver fibrosis as well as hepatocyte epithelial-mesenchymal transition in a mouse model of NASH with type 2 diabetes mellitus, and high-glucose-cultured steatotic human normal liver cells.
[Cell Death Discovery] |
|
|
|
| In view of the key metabolic role of tribbles related homolog 1 (TRIB1) and the impact of proteasome inhibition on hepatic function, researchers explored TRIB1 regulation in two commonly used human hepatocyte models, transformed cell lines HuH-7 and HepG2.
[Scientific Reports] |
|
|
|
| The expression of Y-box binding protein 1 in human liver microarray, mice tissues, and primary mouse hepatic stellate cells was validated to be upregulated in several hepatic fibrosis models.
[Cellular Signalling] |
|  |
|
|
|
| The authors discuss why antifibrotic effects observed in NASH pharmacotherapy trials have been underwhelming and outline potential approaches to improve the likelihood of future clinical success.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Scientists cover the molecular, cellular and organismal aspects of various liver pathologies from a circadian viewpoint, and in particular how circadian dysregulation has a role in the development and progression of these diseases.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| The authors outline the differentiation system of liver non-parenchymal cells from human induced pluripotent stem celld (hiPSCs) and development of in vitro liver disease models using hiPSC-derived liver cells.
[Biochemical Society Transactions] |
|
|
|
|
| The California Institute for Regenerative Medicine (CIRM) awarded Eureka Therapeutics, Inc. a $10.6 million grant to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of pediatric patients with refractory/relapsed liver cancer.
[Eureka Therapeutics, Inc.] |
|
|
|
|
| June 28 – July 1, 2023
Barcelona, Spain |
|
|
|
|
|
| | Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States |
|
|
|
| | University of New South Wales – Sydney, New South Wales, Australia |
|
|
|
| | Centre for Oncology and Immunology – Hong Kong, Hong Kong |
|
|
|
| | University of Geneva – Geneva, Switzerland |
|
|
|
| | University of Utah – Salt Lake City, Utah, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
